<DOC>
	<DOCNO>NCT02023710</DOCNO>
	<brief_summary>Mucosal melanoma rare associate extremely poor prognosis.No effective treatment advance mucosal melanoma patients.Investigators conduct randomized phase II study patient previously untreated metastatic mucosal melanoma characterize efficacy safety bevacizumab combine carboplatin plus paclitaxel .</brief_summary>
	<brief_title>Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy Treat Metastatic Mucosal Melanoma</brief_title>
	<detailed_description>Mucosal melanoma rare associate extremely poor prognosis.It second common subtype Asians.No effective treatment advance mucosal melanoma patients.Malignant melanoma highly vascular tumor vascular endothelial growth factor ( VEGF ) strongly express seem play important role disease progression.A randomize phase II study evaluate activity Bevacizumab combination carboplatin plus paclitaxel ( CPB arm ) patient previously untreated advanced melanoma.Overall response rate 25.5 % , median overall survival time ( OS ) 12.3 month CPB arm . Investigators conduct randomized phase II study patient previously untreated metastatic mucosal melanoma characterize efficacy safety bevacizumab combine carboplatin plus paclitaxel .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically confirm mucosal melanoma metastasis receive systemic treatment . 2 . ECOG performance status 0 , 1 3 . Estimated life expectancy 12 week great 4 . Age 18 year old , male female 5 . At least one measurable site ( diameter≥1cm ) disease ( RECIST 1.1 ) . 6 . Adequate organ function 7 . Without symptom brain metastasis stable neurofunctions . 8 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure 1 . Mutations CKIT BRAFV600E , ask target treatment 2 . Pregnant lactation woman 3 . Acute infection without control . 4 . Heart disease history , cardiac function class≥NYHA II . 5 . HIV positive chronic HBV/HCV active stage . 6 . Brain metastasis primary tumor positive symptom 7 . Need antiepileptic treatment 8 . Organ transplantation history 9 . Hemorrhagic tendency relate history 10 . Renal dialysis patient 11 . Diagnosis second malignancy within last 3 year , except adequately treat . 12 . Current treatment another clinical trial 13 . The improper situation investigator judge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>mucosal melanoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>